SEI Investments’s Ascendis Pharma A/S ASND Stock Holding History

SEI Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.4M	Sell	237,869 -113,277	-32%	-$26.5M	0.06%	374
2026 Q1	$80.3M	Buy	351,146 +69,673	+25%	+$15.6M	0.07%	287
2025 Q4	$60M	Buy	281,473 +76,154	+37%	+$15.7M	0.06%	341
2025 Q3	$40.8M	Sell	205,319 -31,251	-13%	-$5.83M	0.04%	441
2025 Q2	$40.8M	Sell	236,570 -21,443	-8%	-$3.49M	0.05%	412
2025 Q1	$40.2M	Sell	258,013 -5,569	-2%	-$796K	0.05%	388
2024 Q4	$36.3M	Sell	263,582 -10,165	-4%	-$1.34M	0.05%	423
2024 Q3	$40.9M	Buy	273,747 +9,176	+3%	+$1.24M	0.05%	381
2024 Q2	$36.1M	Sell	264,571 -81,615	-24%	-$11.1M	0.05%	382
2024 Q1	$52.3M	Sell	346,186 -15,644	-4%	-$2.23M	0.08%	279
2023 Q4	$45.6M	Sell	361,830 -34,610	-9%	-$3.45M	0.07%	297
2023 Q3	$37.1M	Sell	396,440 -13,944	-3%	-$1.3M	0.07%	310
2023 Q2	$36.6M	Sell	410,384 -65,637	-14%	-$5.71M	0.06%	324
2023 Q1	$51M	Buy	476,021 +38,770	+9%	+$4.44M	0.09%	222
2022 Q4	$53.4M	Sell	437,251 -36,268	-8%	-$4.21M	0.12%	176
2022 Q3	$48.9M	Buy	473,519 +21,718	+5%	+$2.06M	0.11%	190
2022 Q2	$42M	Buy	451,801 +7,242	+2%	+$683K	0.09%	233
2022 Q1	$52.2M	Buy	444,559 +21,868	+5%	+$2.53M	0.1%	192
2021 Q4	$56.9M	Buy	422,691 +33,468	+9%	+$4.98M	0.11%	198
2021 Q3	$62M	Buy	389,223 +90,902	+30%	+$12.4M	0.13%	161
2021 Q2	$39.2M	Buy	298,321 +35,929	+14%	+$4.79M	0.09%	231
2021 Q1	$33.8M	Buy	262,392 +19,290	+8%	+$2.93M	0.09%	232
2020 Q4	$40.6M	Buy	243,102 +8,328	+4%	+$1.38M	0.1%	186
2020 Q3	$36.2M	Buy	234,774 +84,122	+56%	+$12.1M	0.1%	172
2020 Q2	$22.3M	Buy	150,652 +64,466	+75%	+$8.85M	0.07%	279
2020 Q1	$9.71M	Buy	86,186 +20,278	+31%	+$2.63M	0.04%	483
2019 Q4	$9.17M	Buy	65,908 +899	+1%	+$99.9K	0.03%	619
2019 Q3	$6.26M	Buy	65,009 +20,938	+48%	+$2.34M	0.02%	828
2019 Q2	$5.08M	Buy	44,071 +18,971	+76%	+$2.27M	0.02%	924
2019 Q1	$2.95M	Buy	+25,100	New	+$2.2M	0.01%	1150

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SEI Investments's ASND Position: Q2 2026 in Review

SEI Investments reduced its Ascendis Pharma A/S (ASND) stake by 32% in Q2 2026, selling an estimated $26.5M and leaving 237,869 shares worth $63.4M. The position accounts for 0.06% of the portfolio, ranked #374.

SEI Investments first reported a position in ASND in Q1 2019 and has held it in 30 quarters since. The position peaked at $80.3M in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

SEI Investments held 237,869 shares of Ascendis Pharma A/S worth $63.4M as of Q2 2026.
SEI Investments sold 113,277 Ascendis Pharma A/S shares in Q2 2026, an estimated $26.5M.
Ascendis Pharma A/S made up 0.06% of SEI Investments's portfolio in Q2 2026, its #374 holding.
SEI Investments first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 30 quarters since.
SEI Investments's Ascendis Pharma A/S position peaked at $80.3M in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.